Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, Heather Lin, Behrang Amini, Skye C Mayo, Dejka Araujo, Robert S Benjamin, Anthony P Conley, John A Livingston, Joseph Ludwig, Shreyaskumar Patel, Ravin Ratan, Vinod Ravi, Maria A Zarzour, Elise F Nassif Haddad, Michael S Nakazawa, Xiao Zhou, Michael C Heinrich, Neeta Somaiah
Ripretinib and avapritinib have demonstrated activity in the late-line treatment of gastrointestinal stomal tumors (GISTs). We investigated whether patients previously treated with ripretinib benefit from avapritinib, and vice versa. Patients diagnosed with metastatic/unresectable GIST and treated with both drugs at two institutions in 2000-2021 were included. Patients were grouped by drug sequence: ripretinib-avapritinib (RA) or avapritinib-ripretinib (AR). Radiographic response was evaluated using RECIST 1...
February 23, 2024: Cancers